Genmab/ADC Therapeutics To Co-Develop ADC
Espicom View: Interest in antibody drug conjugates is growing rapidly. With two approved next-generation antibody drug conjugates and two in late-stage development, it is clear that there have been many technological advances in the field, specifically with drug linker technology. With each component of the antibody drug conjugate there exists the possibility for improvement, offering almost unlimited opportunity to fine tune therapies. Despite Genmab/ADC Therapeutics opting to use novel agents in their offering, we expect to see a greater number of pharmaceutical companies developing improved versions of older blockbuster drugs, as Roche has done with Kadcyla.
Genmab and ADC Therapeutics have entered into an agreement to develop a new antibody-drug conjugate (ADC) product combining Genmabâs HuMax-TAC antibody and a pyrrolobenzodiazepine (PBD)-based warhead, developed by ADC Therapeutics' partner, Spirogen. The companies have been conducting in vitro and in vivo studies since 2012 to investigate different warhead and linker combinations with HuMax-TAC, and now have the product ready for pre-IND preclinical development. The product will be developed for multiple cancer indications.
Genmab and ADC Therapeutics will each initially have an equal share in the product. In the first instance, ADC Therapeutics will lead and fund preclinical development. Prior to the submission of an IND application, Genmab may elect to retain equal ownership of the product. Genmab will not incur any development costs prior to the IND filing decision and Genmab will maintain a minimum 25 per cent ownership stake in the product as it moves into clinical development. No other financial terms were disclosed.